Results 1 to 10 of about 1,361 (136)
Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma [PDF]
Clinical Cancer ResearchAbstract Purpose: Adavosertib is an oral small-molecule inhibitor of Wee1. The Adult Brain Tumor Consortium conducted a phase I study evaluating adavosertib in combination with radiation (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM), as well as a surgical ...
Jennifer Gantchev +2 more
exaly +5 more sources
Introduction to Single‐Cell Physiologically‐Based Pharmacokinetic (scPBPK) Models
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.ABSTRACT The current investigation introduces single‐cell physiologically based pharmacokinetic (scPBPK) models to gain insight into drug disposition at the cellular scale. The transition from standard PBPK (sPBPK) models to scPBPK models required depiction of expression‐dependent (ED) processes, such as drug metabolism or membrane transport.
Anshul Saini, James M. Gallo
wiley +1 more source
Human Absorption, Metabolism, and Excretion (hAME) Mass Balance Studies in Patients With Cancer
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Radiolabeled mass balance human studies are a critical component of clinical pharmacology programs supporting the development of new investigational drugs. These studies provide information about absorption, metabolism, and excretion (AME) of the parent drug and metabolite(s) in the human body and are normally conducted in healthy volunteers ...
Begoña de las Heras +9 more
wiley +1 more source
Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr +4 more
wiley +1 more source
HemaSphere, Volume 10, Issue 3, March 2026.Abstract TP53 mutations are found in over 50% of tumor types, including myeloproliferative neoplasms (MPNs). MPNs are characterized by a chronic phase, which may progress to secondary acute myeloid leukemia (sAML). Here, we discuss the physiological functions of p53 in hematopoiesis and its deregulation in MPNs.
Suzana da Silva‐Benedito +6 more
wiley +1 more source
MedComm – Oncology, Volume 5, Issue 1, March 2026.Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang +7 more
wiley +1 more source
Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +2 more sources
EIF1AX Nucleolar Condensates Enhance Susceptibilities for the Management of Endometrial Cancer
Advanced Science, Volume 13, Issue 12, 27 February 2026.This schematic illustrates the mechanism of a senolytic strategy in endometrial cancer. EIF1AX facilitates the incorporation of DDX21 into nucleolar condensates, an event that suppresses rDNA transcription and induces cellular senescence. The compound 2,5‐MeC exploits this pathway by promoting EIF1AX nucleolar translocation and condensate formation ...
Chengyu Lv +8 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 1, January 2026.Chemotherapy was not associated with improved survival in localized or metastatic CIC‐rearranged sarcoma. Optimizing local control remains essential, and novel systemic therapies are urgently needed. ABSTRACT Introduction CIC‐rearranged sarcomas (CRS) are rare tumors predominantly affecting young adults.
Talya Wittmann Dayagi +17 more
wiley +1 more source
Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets
British Journal of Pharmacology, Volume 182, Issue 23, Page 5734-5747, December 2025.Abstract Background and Purpose In order to significantly improve the therapeutic treatment of breast cancer, the exploration of underlying genetic and molecular differences is absolutely necessary. Here, our goal was to integrate mutational status of entire pathways to reveal molecular pathway interactions determining survival. Experimental Approach A
Máté Posta, Balázs Győrffy
wiley +1 more source